+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2020

  • ID: 5137290
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 66 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Biogen Inc
  • ChemoCentryx Inc
  • InflaRx NV
  • Mabion SA
  • Pharmapraxis
  • Teijin Pharma Ltd
  • MORE
Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2020

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis - Pipeline Review, H2 2020, provides an overview of the Microscopic Polyangiitis (Cardiovascular) pipeline landscape.

Microscopic polyangiitis (MPA) is a disorder that causes blood vessel inflammation (vasculitis), which can lead to organ damage. Symptoms include leg swelling and dark-colored urine from kidney problems, skin bumps and spots, numbness due to nerve damage, fever, tiredness and weakness.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Microscopic Polyangiitis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 2, 1, 1 and 1 respectively.

Microscopic Polyangiitis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Microscopic Polyangiitis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Microscopic Polyangiitis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (Cardiovascular)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biogen Inc
  • ChemoCentryx Inc
  • InflaRx NV
  • Mabion SA
  • Pharmapraxis
  • Teijin Pharma Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Microscopic Polyangiitis (MPA) - Overview
  • Microscopic Polyangiitis (MPA) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Microscopic Polyangiitis (MPA) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
  • Biogen Inc
  • ChemoCentryx Inc
  • InflaRx NV
  • Mabion SA
  • Pharmapraxis
  • Teijin Pharma Ltd
  • Microscopic Polyangiitis (MPA) - Drug Profiles
  • avacopan - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vilobelimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Microscopic Polyangiitis (MPA) - Dormant Projects
  • Microscopic Polyangiitis (MPA) - Discontinued Products
  • Microscopic Polyangiitis (MPA) - Product Development Milestones
  • Featured News & Press Releases
  • Jan 30, 2020: The CHMP recommended extensions of indication for MabThera
  • Sep 30, 2019: Roche’s Rituxan secures approval for first paediatric indication
  • Jun 12, 2019: FDA grants priority review to Genentech’s Rituxan (Rituximab) in children with two rare blood vessel disorders
  • Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
  • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
  • Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
  • Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Microscopic Polyangiitis (MPA), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Microscopic Polyangiitis (MPA) - Pipeline by Biogen Inc, H2 2020
  • Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx Inc, H2 2020
  • Microscopic Polyangiitis (MPA) - Pipeline by InflaRx NV, H2 2020
  • Microscopic Polyangiitis (MPA) - Pipeline by Mabion SA, H2 2020
  • Microscopic Polyangiitis (MPA) - Pipeline by Pharmapraxis, H2 2020
  • Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Ltd, H2 2020
  • Microscopic Polyangiitis (MPA) - Dormant Projects, H2 2020
  • Microscopic Polyangiitis (MPA) - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Microscopic Polyangiitis (MPA), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Targets, H2 2020
  • Number of Products by Stage and Targets, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Biogen Inc
  • ChemoCentryx Inc
  • InflaRx NV
  • Mabion SA
  • Pharmapraxis
  • Teijin Pharma Ltd
Note: Product cover images may vary from those shown
Adroll
adroll